Most driver-positive NSCLC (such as those harboring EGFR or ALK alterations) typically do not respond well to standard PD-1/PD-L1 checkpoint inhibitors and are instead treated with target-specific tyrosine kinase inhibitors [2, 71]. Here, ALK is linked to non-small cell lung carcinoma.